Mounjaro (tirzepatide) prior authorization denied appeal
GIP/GLP-1 for type 2 diabetes
Typical PA criteria
- Type 2 diabetes (ICD-10 E11.x)
- A1C above threshold
- Trial of metformin and a GLP-1
Why your PA was denied
- Off-label use for weight loss
- Step therapy not completed
- Quantity limit exceeded
Evidence that overturns the denial
- ✓Diabetes diagnosis on chart and claim
- ✓A1C trend
- ✓Prior therapy documentation
- ✓SURPASS trial citation
Approval typically requires both a metformin trial and a prior GLP-1 trial.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Mounjaro (tirzepatide) prior authorization denied?+
The most common reasons are: Off-label use for weight loss; Step therapy not completed; Quantity limit exceeded. Your denial letter names the specific criteria you did not meet.
How do I appeal a Mounjaro (tirzepatide) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Mounjaro (tirzepatide) denial?+
Diabetes diagnosis on chart and claim; A1C trend; Prior therapy documentation.
What if the plan excludes Mounjaro (tirzepatide) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Saxenda (liraglutide)
- Humira (adalimumab)